Hepanext 300 Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily in the management of cholestatic liver diseases. It is indicated for the treatment of primary biliary cholangitis (PBC), where it helps to improve liver function by reducing the cytotoxicity of bile acids and promoting bile flow. Ursodeoxycholic Acid works by displacing more hydrophobic, potentially hepatotoxic bile acids, thereby protecting hepatocytes from bile acid-induced apoptosis and inflammation. Additionally, it is employed in the dissolution of cholesterol gallstones in patients who are not suitable candidates for surgery. Hepanext 300 is administered orally, with dosage and duration tailored according to the specific clinical condition and patient response. Commonly, it is well tolerated, though some patients may experience mild gastrointestinal disturbances such as diarrhea, nausea, or abdominal discomfort. Regular monitoring of liver function tests is recommended to assess therapeutic efficacy and detect potential adverse effects. Hepanext 300 should be used under medical supervision, especially in patients with advanced liver disease or cirrhosis. It is contraindicated in patients with complete biliary obstruction and should be used cautiously during pregnancy and lactation.